ABBV Jan 2025 170.000 call
| Previous close | 12.80 |
| Open | 11.95 |
| Bid | 11.35 |
| Ask | 14.50 |
| Strike | 170.00 |
| Expiry date | 2025-01-17 |
| Day's range | 11.90 - 11.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.31k |
- Yahoo Finance Video
PCE inflation data, ExxonMobil, earnings: What to Watch
March's Personal Consumption Expenditures (PCE) index — the Federal Preserve's preferred inflation gauge — is due out tomorrow morning, as many other companies prepare to publish their latest earnings figures, including oil giants ExxonMobil (XOM) and Chevron (CVX). Yahoo Finance's Julie Hyman and Jared Blikre list the top headlines and data investors should be paying attention to on Friday, April 25. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.
ReutersCigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
